4Q3V image
Entry Detail
PDB ID:
4Q3V
Title:
Crystal structure of Schistosoma mansoni arginase in complex with inhibitor BEC
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2014-04-12
Release Date:
2014-07-16
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.21
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 21 3
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Arginase
Chain IDs:A, B, C, D
Chain Length:385
Number of Molecules:4
Biological Source:Schistosoma mansoni
Primary Citation
Crystal Structure of Schistosoma mansoni Arginase, a Potential Drug Target for the Treatment of Schistosomiasis.
Biochemistry 53 4671 4684 (2014)
PMID: 25007099 DOI: 10.1021/bi5004519

Abstact

The X-ray crystal structure of arginase from Schistosoma mansoni (SmARG) and the structures of its complexes with several amino acid inhibitors have been determined at atomic resolution. SmARG is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to form l-ornithine and urea, and this enzyme is upregulated in all forms of the parasite that interact with the human host. Current hypotheses suggest that parasitic arginases could play a role in host immune evasion by depleting pools of substrate l-arginine that would otherwise be utilized for NO biosynthesis and NO-dependent processes in the immune response. Although the amino acid sequence of SmARG is only 42% identical with that of human arginase I, residues important for substrate binding and catalysis are strictly conserved. In general, classical amino acid inhibitors such as 2(S)-amino-6-boronohexanoic acid (ABH) tend to bind more weakly to SmARG than to human arginase I despite identical inhibitor binding modes in each enzyme active site. The identification of a patch on the enzyme surface capable of accommodating the additional Cα substitutent of an α,α-disubstituted amino acid inhibitor suggests that such inhibitors could exhibit higher affinity and biological activity. The structures of SmARG complexed with two different α,α-disubstituted derivatives of ABH are presented and provide a proof of concept for this approach in the enhancement of enzyme-inhibitor affinity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures